Appendix Table 5.

Factors Associated With Detectable VL in Adjusted Models Among Patients Receiving ART in 2010 to 2015

Covariate	Joint Longitudinal Survival Model*			Linear Mixed Model†
	OR	95% CI	P Value	Relative VL	95% CI	P Value
Integrase strand transfer inhibitor use	0.67	0.63–0.72	<0.001	0.78	0.76–0.81	<0.001
Female	1.23	1.11–1.36	<0.001	1.14	1.07–1.21	<0.001
Age (per decade, centered at 40 y)	0.69	0.67–0.72	<0.001	0.85	0.83–0.87	<0.001
Race/ethnicity (reference is white race)
Black	2.09	1.89–2.30	<0.001	1.54	1.46–1.65	<0.001
Hispanic	0.84	0.74–0.96	0.01	0.91	0.84–0.98	0.014
Other	0.88	0.73–1.06	0.2	0.93	0.83–1.04	0.197
Calendar time (year of cohort entry, centered around 2010)	1.14	1.10–1.17	<0.001	0.98	0.96–1.00	0.016
Years of follow-up	0.79	0.78–0.81	<0.001	0.78	0.77–0.79	<0.001

ART = antiretroviral therapy; OR = odds ratio; VL = viral load.

^*Outcome is detectable VL (>400 copies/mL).

^†Outcome is VL in log₁₀ copies/mL.